1169 related articles for article (PubMed ID: 15752732)
21. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
Huang H; Chang EJ; Ryu J; Lee ZH; Lee Y; Kim HH
Biochem Biophys Res Commun; 2006 Dec; 351(1):99-105. PubMed ID: 17052691
[TBL] [Abstract][Full Text] [Related]
22. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
23. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
25. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
26. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
27. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.
Kim JH; Kim K; Youn BU; Jin HM; Kim N
Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061
[TBL] [Abstract][Full Text] [Related]
28. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
[TBL] [Abstract][Full Text] [Related]
30. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1.
Kwak HB; Yang D; Ha H; Lee JH; Kim HN; Woo ER; Lee S; Kim HH; Lee ZH
Exp Mol Med; 2006 Jun; 38(3):256-64. PubMed ID: 16819284
[TBL] [Abstract][Full Text] [Related]
31. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
[TBL] [Abstract][Full Text] [Related]
32. RANK-L induces the expression of NFATc1, but not of NFkappaB subunits during osteoclast formation.
Zhu LL; Zaidi S; Moonga BS; Troen BR; Sun L
Biochem Biophys Res Commun; 2005 Jan; 326(1):131-5. PubMed ID: 15567162
[TBL] [Abstract][Full Text] [Related]
33. Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor.
Day CJ; Kim MS; Stephens SR; Simcock WE; Aitken CJ; Nicholson GC; Morrison NA
J Cell Biochem; 2004 Feb; 91(2):303-15. PubMed ID: 14743390
[TBL] [Abstract][Full Text] [Related]
34. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
[TBL] [Abstract][Full Text] [Related]
36. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
Wattel A; Kamel S; Prouillet C; Petit JP; Lorget F; Offord E; Brazier M
J Cell Biochem; 2004 May; 92(2):285-95. PubMed ID: 15108355
[TBL] [Abstract][Full Text] [Related]
37. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
Ren W; Li XH; Chen BD; Wooley PH
J Orthop Res; 2004 Jan; 22(1):21-9. PubMed ID: 14656655
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
39. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
40. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.
Park CK; Lee Y; Chang EJ; Lee MH; Yoon JH; Ryu JH; Kim HH
Biochem Pharmacol; 2008 Jun; 75(11):2175-82. PubMed ID: 18433733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
